PLAINSBORO, N.J., Sept. 29, 2017 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved Fiasp ® (insulin aspart injection) 100 Units/mL, a fast ...

The FDA approved Novo Nordisk’s Fiasp, an insulin aspart injection to be used as a mealtime insulin option for children with diabetes, the company announced Jan. 6. Advertisement Maia Anderson ...

Novo Nordisk NVO announced that the FDA has approved its fast-acting mealtime insulin aspart, Fiasp, for the treatment of adults with diabetes. The.

PLAINSBORO, N.J., Feb. 5, 2018 /PRNewswire/ -- Novo Nordisk today announced the availability of two new diabetes medications, Ozempic ® (semaglutide) injection 0.5 mg or 1 mg and Fiasp ...

For Novo Nordisk and its new fast-acting mealtime insulin, a second try at the FDA gatekeepers was enough to secure an approval. The drugmaker's Fiasp won its U.S.

Novo Nordisk has received the Food and Drug Administration’s clearance for Fiasp (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic ...

COPENHAGEN, Sept 12 (Reuters) - Novo Nordisk said in an analysis presented at the Annual Meeting of the European Association For The Study Of Diabetes: * Novo's Fiasp (fast-acting insulin aspart ...

Ellison says the settlement requires Novo Nordisk to provide insulin products—including Novolog, Tresiba, Fiasp, and Novolin, at any formulation and via any delivery method—at $35 per monthly ...

Novo Nordisk A/SNVO announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults. A look.

Sept 29 (Reuters) - NOVO NORDISK SAYS. Sept 29 (Reuters) - NOVO NORDISK SAYS. Skip to main content. Exclusive news, data and analytics for financial market professionals Learn more about Refinitiv.

Novo Nordisk accounts for 32% of the global diabetes market, including roughly half of both the $15 billion insulin therapy market and the more than $30 billion GLP-1 market .

Novo Nordisk NVO announced that the FDA has approved its fast-acting mealtime insulin aspart, Fiasp, for the treatment of adults with diabetes. The FDA approval was based on results from a phase ...